[Ovarian tumors in pregnancy--proposals of diagnosis and treatment].

Ginekol Pol

Klinika Chirurgii Ginekologicznej Instytutu Centrum Zdrowia Matki Polki w Łodzi.

Published: March 2004

We present the review of the literature and the proposals of the exact diagnosing and therapy of the ovarian tumors complicating pregnancy. The incidence of ovarian tumors in pregnant women is estimated on 1/1000 deliveries. The coexistence of an ovarian tumor with pregnancy presents problems to both the clinician (obstetrician, oncologist) and the patient. Depending of the increasing uterus during pregnancy, the appropriate diagnosis of adnexal mass is based on the initial pelvic and ultrasound examination. Most of ovarian tumors in pregnant women are asymptomatic and when they are unsuspicious simple cysts or cystic teratomas the conservative management is recommended. In cases of complex masses and/or torsion, rupture, hemorrhage the surgical intervention by laparotomy (in some cases laparoscopy) is required. The possibility of malignancy and its therapeutic implications (hysterectomy, salpingo-oophorectomy, delay to delivery) must be discussed with the patient and her family (the lives of two human beings together are affected).

Download full-text PDF

Source

Publication Analysis

Top Keywords

ovarian tumors
12
tumors pregnant
8
pregnant women
8
[ovarian tumors
4
tumors pregnancy--proposals
4
pregnancy--proposals diagnosis
4
diagnosis treatment]
4
treatment] review
4
review literature
4
literature proposals
4

Similar Publications

Gemcitabine, a cytosine analogue, is a cytotoxic agent commonly used in the treatment of patients with a variety of solid tumours, including non-small cell lung cancer, cholangiocarcinoma and breast, pancreatic, testicular and ovarian cancers. Although generally well-tolerated, several reports suggest that it can rarely cause myositis. We present a case of gemcitabine-induced myositis in a patient with pancreatic adenocarcinoma and review the literature on this topic.

View Article and Find Full Text PDF

Purpose: Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer specific mortality (PCSM) and overall survival (OS) among patients undergoing radical prostatectomy with digitized RP specimens.

Materials And Methods: The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993-2001 to cancer screening or control.

View Article and Find Full Text PDF

Purpose: Ovarian-Adnexal Reporting and Data System (O-RADS) US provides a standardized lexicon for ovarian and adnexal lesions, facilitating risk stratification based on morphological features for malignancy assessment, which is essential for proper management. However, systematic determination of inter-reader reliability in O-RADS US categorization remains unexplored. This study aimed to systematically determine the inter-reader reliability of O-RADS US categorization and identify the factors that affect it.

View Article and Find Full Text PDF

Background: Borderline ovarian tumors (BOTs) differ from ovarian carcinomas in their clinical presentation and behavior, yet their molecular characteristics remain poorly understood. This study aims to address this gap by integrating whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to compare BOTs with high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), and clear-cell carcinoma (CCC).

Objective: To elucidate the molecular features of BOTs and evaluate their similarities and differences in comparison to HGSC, EC, and CCC.

View Article and Find Full Text PDF

Genomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination deficiency (HRD) characterized by mutations in DNA damage repair genes such as for treatment with PARP inhibitors. However, recent studies have shown that some epithelial ovarian tumors respond to PARP inhibitors irrespective of their HRD or mutation status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!